GSK’s Arexvy RSV vaccine, currently approved for adults 60 and older, shows positive preliminary data in adults aged 18-49 at increased risk for respiratory illness, potentially broadening its reach to a larger population. This development comes as both GSK and Pfizer face declining sales due to narrow age recommendations for their RSV vaccines.
GSK has announced positive results from a phase 3 trial showing that its RSV vaccine, Arexvy, can be safely and effectively co-administered with the shingles vaccine, Shingrix, in adults aged 50 and older. This offers a convenient option for seniors seeking protection against both respiratory syncytial virus (RSV) and shingles.
